Search

Displaying results 161 - 170 of 4018 in total
  1. Target

    Bone morphogenetic protein receptor type-1B

    go.drugbank.com/bio_entities/BE0009415
    TargetHumans

    On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SM...

    Polypeptides: Bone morphogenetic protein receptor type-1B
  2. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected

  3. Drug

    Carboplatin

    go.drugbank.com/drugs/DB00958
    ApprovedInvestigational

    [A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]

  4. Drug

    Primidone

    go.drugbank.com/drugs/DB00794
    ApprovedVet approved

    [A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112]

  5. Drug

    Human calcitonin

    go.drugbank.com/drugs/DB06773
    Approved

    Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calci...

    Categories: Bone Density Conservation Agents
  6. Drug

    Chondroitin sulfate

    go.drugbank.com/drugs/DB09301
    ApprovedInvestigationalNutraceutical

    Depending on the predominating disaccharide unit, it will present different biological activities.

    Mixtures: Gluco-con capsules, GLUCOSAMINA CON CONDROITINA 500/400 MG CAPSULACategories: Antiinflammatory and Antirheumatic Products, Non-Steroids
  7. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It gained approval by European Commission in March 2009. … Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity.

  8. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    [A242277] It results from a gain-of-function missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and in length. … Endogenous CNP, first described in 1998, is primarily responsible for the stimulation of chondrocytes and long bone growth via activity at the NPR-B receptor, making it an attractive target in the treatment

    Categories: Drugs for Treatment of Bone Diseases, Drugs Affecting Bone Structure and Mineralization
  9. Drug

    Acyclovir

    go.drugbank.com/drugs/DB00787
    ApprovedInvestigational

    [L7321] Acyclovir was granted FDA approval on 29 March 1982.[L7318]

    Products: ENTO TOPICO MARCA AVIRAL
  10. Drug

    Glyburide

    go.drugbank.com/drugs/DB01016
    ApprovedInvestigational

    [A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120] … [L8123] Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.

    Mixtures: MELLIMET G ® TABLETAS RECUBIERTAS CON PELÍCULA 500MG + 2.5 MG